Non-small cell lung cancerReal-worldAfatinibPredictive factorIntroduction Afatinib is used to treat patients with advanced non-small cell lung cancer (NSCLC) harboring common EGFR mutations; however, the clinicopathological factors that predict this drug's effectiveness in real-world settings remain ...
et al. The significance of co-mutations in EGFR-mutated non-small cell lung cancer: optimizing the efficacy of targeted therapies? Lung Cancer 181, 107249 (2023). Article CAS PubMed Google Scholar Blaquier, J. B. et al. Tackling osimertinib resistance in EGFR-mutant non-small cell lung ...
Cancer-associated fibroblasts promote EGFR-TKI resistance via the CTHRC1/glycolysis/H3K18la positive feedback loop Chen Zhang Wenxin Zhou Renhua Guo ResearchOpen Access26 Feb 2025Oncogene P: 1-15 Translating premalignant biology to accelerate non-small-cell lung cancer interception ...
The discovery of the association between EGFR mutations and the efficacy of EGFR tyrosine-kinase inhibitors (TKIs) has revolutionized the treatment paradigm for patients with non-small-cell lung cancer (NSCLC). Currently, third-generation EGFR TKIs, which are often characterized by potent central nerv...
Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component. Mol Cancer Ther Published on-line August 14, 2012." NSCL-16 · Continuation maintenance chemotherapy: > Bevacizumab + pemetrexed added with category 2A recommendation ...
Impact of EGFR mutation analysis in non-small cell lung cancer. The discovery of mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer (NSCLC) accelera... H Yamamoto,S Toyooka,T Mitsudomi - 《Lung Cancer》 被引量: 0发表...
Identifying EGFR mutations and other molecular changes has become more crucial in the management of non-small cell lung cancer (NSCLC) than ever before. Although the histologic subtypes in patients with advanced NSCLC remain valid in determining treatment options, the detection of specific molecular ...
(ctDNA) before starting osimertinib therapy in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) who had progressed under treatment with EGFR tyrosine kinase inhibitors (TKIs).Patients and Methods We enrolled 141 patients with advanced EGFR T790M-positive NSCLC who underwent ...
bIncludes one EGFR-positive patient. cThe reasons were clinical progression (n = 3), physician did not want to delay patient surgery (n = 1), physician did not consider the patient a good surgical candidate (n = 1) and physician discontinued patient from the study because of...
availability of 3 generations of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has provided oncologists with a potentially confusing choice for the treatment of EGFR mutation-positive non-small-cell lung cancer. ...